Granules India bags USFDA nod for Venlafaxine Hydrochloride ER Capsules

Venlafaxine HCl extended-release capsules are indicated for the treatment of Major Depressive Disorder, Generalized Anxiety Disorder, Social Anxiety Disorder and Panic Disorder.

Published On 2023-05-19 06:00 GMT | Update On 2023-05-19 06:16 GMT

Hyderabad: Drugmaker, Granules India Limited, announced today that the US Food & Drug Administration (US FDA) has approved its Abbreviated New Drug Application (ANDA) for Venlafaxine Hydrochloride Extended-Release Capsules USP, 37.5 mg, 75 mg, and 150 mg.

It is bioequivalent to the reference listed drug product (RLD), Effexor XR Extended-Release Capsules of Upjohn US 2 LLC.

Venlafaxine HCl extended-release capsules are indicated for the treatment of Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD) and Panic Disorder (PD).

Granules now have a total of 56 ANDA approvals from US FDA (54 Final approvals and 2 tentative approvals). The current annual U.S. market for Venlafaxine ER Capsules is approximately $153 Million, according to MAT Mar 2023, IQVIA/IMS Health.

Medical Dialogues team had earlier reported that the USFDA had approved the Abbreviated New Drug Application (ANDA) filed by Granules Pharmaceuticals, Inc (GPI) for Bupropion Hydrochloride Extended-Release Tablets USP (XL), 150 mg and 300 mg.

Granules India Limited, incorporated in 1991 is a vertically integrated Indian pharmaceutical company headquartered at Hyderabad. Granules is among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). Its products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, US, and UK. The Company has 7 manufacturing facilities out of which 6 are in India and 1 in the USA and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC, and HALAL.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Granules India bags USFDA nod for Venlafaxine Hydrochloride ER Capsules

Venlafaxine HCl extended-release capsules are indicated for the treatment of Major Depressive Disorder, Generalized Anxiety Disorder, Social Anxiety Disorder and Panic Disorder.

Similar News

Pfizer to buy obesity drug maker Metsera

Sanofi SAR446268 wins USFDA fast track designation for non-congenital myotonic dystrophy type 1

AstraZeneca-Daiichi Sankyo get USFDA grants priority review for Enhertu combo for 1st line HER2+ Breast cancer treatment

SII, Vidal Health join hands on HPV vaccine access

Allahabad HC Flags Procedural Flaws, Quashes Drugs Case Summons Against Pharma Firm

Shashank Srowthy to succeed Lokesh Chandak as CFO of P&G Health

Delhi HC Orders Fresh Inspection of Palamur Biosciences After PETA Allegations

Jubilant Pharmova names Arun Kumar Sharma as interim CFO